Preclinical and translational data demonstrate the immunologic effects of BRAF and MEK inhibitors, including influx of CD4 + and CD8 + T cells into tumors, decreased regulatory T cells (Tregs), decreased MDSCs, and upregulation of melanoma antigens [37]. Here, CD8A is linked to melanoma.